ASCO 指南:涎腺恶性肿瘤的管理
ASCO 召集多学科专家组,检索 2000 至 2020 年文献,针对涎腺恶性肿瘤管理制定循证推荐。共纳入 293 项相关研究,围绕术前评估、诊断与治疗性手术、放疗技术、全身治疗作用及随访六个主要临床问题给出推荐。
要点
- 推荐覆盖涎腺恶性肿瘤诊断、术前评估及不同组织学类型的治疗选择。
- 证据基础来自 293 项研究,含系统综述、荟萃分析、随机对照试验及观察性研究。
- 专家组就手术、放疗技术和全身治疗作用形成循证推荐或非正式共识。
核心结论
- ASCO 基于 2000 至 2020 年文献制定涎腺恶性肿瘤管理的循证推荐。
研究设计与样本
- ASCO 召集肿瘤内科、外科肿瘤、放射肿瘤、神经放射、病理及患者倡导专家组成专家组。
- 文献检索纳入系统综述、荟萃分析、随机对照试验及前瞻性和回顾性比较观察研究,发表时间为 2000 至 2020 年。
- 文献检索共识别 293 项相关研究作为证据基础。
主要发现
- 指南涉及六个主要临床问题,包括术前评估、手术诊断与治疗性操作、放疗技术、全身治疗作用及随访评估的子问题。
- 关注结局包括生存、诊断准确性、疾病复发和生活质量。
关键数值与推荐
- 在可能的情况下,针对涎腺恶性肿瘤患者的诊断和术前评估、治疗性操作及不同组织学类型的治疗选择制定循证推荐。
- 专家组使用可用证据和非正式共识制定循证指南推荐。
临床怎么用
- 临床医生可参照本指南进行涎腺恶性肿瘤的术前评估、手术及放疗决策。
- 不同组织学类型的涎腺恶性肿瘤应参考相应治疗推荐选择治疗方式。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To provide evidence-based recommendations for practicing physicians and other healthcare providers on the management of salivary gland malignancy. METHODS: ASCO convened an Expert Panel of medical oncology, surgical oncology, radiation oncology, neuroradiology, pathology, and patient advocacy experts to conduct a literature search, which included systematic reviews, meta-analyses, randomized controlled trials, and prospective and retrospective comparative observational studies published from 2000 through 2020. Outcomes of interest included survival, diagnostic accuracy, disease recurrence, and quality of life. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: The literature search identified 293 relevant studies to inform the evidence base for this guideline. Six main clinical questions were addressed, which included subquestions on preoperative evaluations, surgical diagnostic and therapeutic procedures, appropriate radiotherapy techniques, the role of systemic therapy, and follow-up evaluations. RECOMMENDATIONS: When possible, evidence-based recommendations were developed to address the diagnosis and appropriate preoperative evaluations for patients with a salivary gland malignancy, therapeutic procedures, and appropriate treatment options in various salivary gland histologies.Additional information is available at www.asco.org/head-neck-cancer-guidelines.
引用
- Geiger JL, Ismaila N, Beadle B, et al. Management of Salivary Gland Malignancy: ASCO Guideline. J Clin Oncol. 2021. PMID: 33900808. doi:10.1200/JCO.21.00449
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。